{
    "2020-03-29": [
        [
            {
                "time": "",
                "original_text": "【光大医药 | 年报点评】云南白药：Q4收入端提速，“期权+回购”组合激励方案超预期",
                "features": {
                    "keywords": [
                        "云南白药",
                        "Q4",
                        "收入端提速",
                        "期权",
                        "回购",
                        "激励方案"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "云南白药（000538）：业绩增长平稳，新白药激励前行【2019年年报点评|西南医药朱国广/杜向阳团队】",
                "features": {
                    "keywords": [
                        "云南白药",
                        "业绩增长",
                        "平稳",
                        "激励"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}